Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Frequent deregulation of cyclin-dependent kinase (CDK) activation associated with loss of
cell cycle control was found in most of human cancers. A recent development of a new class …

Cyclin-dependent kinases (Cdks) play essential roles in the intracellular controls of the cell
cycles. Roscovitine,[2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine] …

Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer
agents usually target several CDKs in cells. Some of them are also able to increase cellular …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Roscovitine (ROSC), a selective blocker of cyclin‐dependent kinases (CDKs) efficiently
inhibits proliferation of exponentially growing human MCF‐7 breast cancer cells by induction …

Increased expression and activity of proteins driving cell cycle progression as well as
inactivation of endogenous inhibitors of cyclin-dependent kinases (CDKs) enhance the …

We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that
roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin …

[2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylp urine](roscovitine) is a
potent and selective inhibitor of cyclin-dependent kinases cdc2 and cdk2. In this study, we …

Tumor suppressor p53 promotes cell death in response to environmental stress signals
including DNA damage, hypoxia and aberrant proliferative signals like oncogene activation …